EGFR Mutation and TKI Treatment Promote Secretion of Small Extracellular Vesicle PD-L1 and Contribute to Immunosuppression in NSCLC

In Asian populations with non-small-cell lung cancer (NSCLC), <i>EGFR</i> mutations are highly prevalent, occurring in roughly half of these patients. Studies have revealed that individuals with <i>EGFR</i> mutation typically fare worse with immunotherapy. In patients who received EGFR tyrosine kina...

Полное описание

Библиографические подробности

Главные авторы:	Hai-Ming Liu, Zi-Li Yu, Hou-Fu Xia, Lin-Zhou Zhang, Qiu-Yun Fu, Yi Wang, Hong-Yun Gong, Gang Chen
Формат:	Artigo
Язык:	Inglês
Опубликовано:	MDPI AG 2024-07-01
Серии:	Biomolecules
Предметы:	<i>EGFR</i>-mutant NSCLC TKIs sEV PD-L1 immunotherapy
Online-ссылка:	https://www.mdpi.com/2218-273X/14/7/820
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!